CapsoVision reported second quarter 2026 revenue of $3.6 million, a 10% increase year-over-year, driven by a 13% rise in capsule sales offset by a 3% decline in average selling price. Gross profit was $1.9 million with a 51% margin, while operating expenses rose to $9.5 million due to clinical trial and development costs. The company holds $9.1 million in cash and announced the international launch of its AI Highlights feature, anticipating FDA clearance by late Q3 2026. Additionally, CapsoVision entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald for an at-the-market program allowing up to $100 million in common stock sales. The company operates in the medical technology industry, developing advanced imaging and AI-enabled capsule endoscopy solutions.
